Announcing Veeva AI
Rhea-AI Summary
Veeva Systems has announced Veeva AI, a major initiative adding artificial intelligence capabilities to their Vault Platform and applications. The AI enhancement aims to boost productivity across clinical, regulatory, safety, quality, medical, and commercial sectors through AI Agents and AI Shortcuts.
The platform will feature application-specific AI Agents that understand context, include safeguards, and securely access Veeva data. Users can customize these agents and create new ones for specific needs. AI Shortcuts allow users to set up personal automations for common tasks.
Key features include:
- LLM-agnostic design supporting major language models
- Flexible deployment with Veeva-supplied or customer-specific LLMs
- Secure data handling for each customer
- Simple subscription fee structure
The first release is scheduled for December 2025, with licensing at the Vault level.
Positive
- Major AI integration across all Veeva applications from clinical to commercial, potentially increasing operational efficiency
- Platform agnostic approach supporting multiple LLMs, offering flexibility to customers
- Revenue potential through new subscription-based licensing model at Vault level
- AI integration designed for quick deployment with existing applications, reducing implementation costs
- Customizable AI Agents allowing company-specific use cases, increasing product value proposition
Negative
- Implementation timeline extends to December 2025, potentially lagging behind competitors
- Additional subscription fees required for AI features may impact customer adoption
- Dependency on third-party LLMs could pose integration and performance risks
News Market Reaction 1 Alert
On the day this news was published, VEEV gained 2.60%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Major new initiative will add AI to Veeva applications and the Veeva Vault Platform to help automate critical industry-specific functions and improve productivity from clinical to commercial
Veeva AI Agents can be deployed quickly with high impact because they understand the Veeva application context, have application-specific prompts and safeguards, and have direct, secure access to Veeva application data, documents, and workflows. Customers can configure and extend Veeva-delivered AI Agents and build custom AI Agents to address company-specific use cases. AI Agents can be used through a chatbot user interface or called via the AI API.
Veeva AI Shortcuts empower end users with the ability to easily set up personal AI-powered automations to accomplish frequent user-specific tasks such as helping with workflows, generating insights, or researching a topic.
"GenAI is a new computing paradigm that will significantly increase productivity for knowledge workers," said Veeva CEO Peter Gassner. "Core applications give you structured data, business rules and workflow. They execute with the speed, consistency, and scale we expect from computers. GenAI brings the more human-like ability to derive answers and insights from ambiguous situations that deal with language, context, and broad-based knowledge. Core applications and GenAI working seamlessly together will bring significant productivity gains."
Veeva AI is LLM agnostic and will support most major large language models. Customers may use a Veeva-supplied LLM or configure Veeva AI to use a customer-specific LLM. Regardless of deployment or which LLM is used by a customer, Veeva AI keeps customer data secure for each customer.
"Our customers depend on Veeva applications for some of their most critical industry-specific processes from clinical to commercial. They want to use AI to improve productivity and ultimately get treatments to patients faster," said CEO Peter Gassner. "Adding Veeva AI to our core applications will help make AI simple, secure, and compliant for life sciences companies of all sizes."
The first release of Veeva AI is planned for December 2025 and will be licensed at the Vault level with a simple and reasonable subscription fee to encourage industry adoption that is both broad and thoughtful.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services, including certain of our new solutions and applications that are still under development or not generally available. These statements are based on our current expectations. Actual results, availability, and any future events relating to these products and services could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-K for the fiscal year ended January 31, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 9 and 10), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Maria Scurry
Veeva Systems
781-366-7617
maria.scurry@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/announcing-veeva-ai-302440862.html
SOURCE Veeva Systems